Long-Term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
The incidence of hepatocellular carcinoma (HCC) increases with age, but protective antibody responses decrease with time after infants are immunized against hepatitis B virus (HBV). We investigated whether immunization of infants against HBV prevents against their development of HCC as adults. We also searched for strategies to maximize the cancer-preventive effects.
Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Direct-acting antivirals have become widely used for patients with chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are excellent and early improvements in liver function, at least in a proportion of patients, have been observed but the longer term impact of viral clearance on end-stage liver disease complications is unclear.
“Aiming for cure in HBV and HDV infection”
Chronic hepatitis B virus (HBV) infection continues to be a major health burden worldwide. Currently available antiviral treatment options for chronic hepatitis B include pegylated interferon alpha2a (PEG-IFN) or nucleos(t)ide analogues (NAs).
Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound
Hepatitis B virus (HBV) RNA in serum has recently been linked to efficacy and prognosis of chronic hepatitis B (CHB) treatment. This study explored the nature, origin, underlying mechanisms, and potential clinical significance of serum HBV RNA.
EpCAM-Regulated Intramembrane Proteolysis Induces a Cancer Stem Cell-like Gene Signature in Hepatitis B Virus-infected Hepatocytes
Hepatocytes in which the hepatitis B virus (HBV) is replicating exhibit loss of the chromatin modifying Polycomb Repressive Complex 2 (PRC2), resulting in re-expression of specific, cellular PRC2-repressed genes. Epithelial Cell Adhesion Molecule (EpCAM) is a PRC2-repressed gene, normally expressed in hepatic progenitors, but re-expressed in hepatic cancer stem cells (hCSCs). Herein, we investigated the functional significance of EpCAM re-expression in HBV-mediated hepatocarcinogenesis.
Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study
Response-guided therapy has been confirmed to be an effective strategy for the treatment of chronic hepatitis C in the peginterferon (PegIFN) era, but no randomized trial utilizing this strategy has been conducted in chronic hepatitis B.
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population.
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B
GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hepatitis B virus (HBV)-specific T-cell responses. We evaluated the safety, tolerability and efficacy of GS-4774 in patients with chronic HBV infection.
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury
Chronic outcome following acute idiosyncratic drug-induced liver injury (DILI) is not yet defined. This prospective, long-term follow-up study aimed to analyze time to liver enzyme resolutions to establish the best definition and risk factors of DILI chronicity.
Biliary atresia and other cholestatic childhood diseases: Advances and future challenges
Biliary Atresia and other cholestatic childhood diseases are rare conditions affecting the function and/or anatomy along the canalicular-bile duct continuum, characterised by onset of persistent cholestatic jaundice during the neonatal period.